Abstract
The latest asthma guidelines are characterized by an increased focus on asthma control and individualized treatment to reduce the patient's impairment and risk of exacerbations. The main components of care include frequent assessment of control and monitoring, patient education, control of environmental triggers, and evaluation of the effectiveness of medications. Failure to treat comorbid conditions, such as rhinosinusitis, and insufficient use of spirometry or peak-flow monitoring are common pitfalls. Inhaled corticosteroids (ICSs) continue to be the mainstay of therapy. Long-acting ß2-agonists are the preferred add-on treatment for patients with persistent asthma who have not adequately responded to an ICS alone. For patients with poorly controlled asthma, close monitoring at 2- to 6-week intervals is recommended. Once control is achieved, follow-up at 1- to 6-month intervals is appropriate.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 481-487 |
| Number of pages | 7 |
| Journal | Journal of Respiratory Diseases |
| Volume | 29 |
| Issue number | 12 |
| State | Published - Dec 2008 |
Fingerprint
Keywords
- Allergy
- Asthma
- NAEPP guidelines
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
Cite this
The NAEPP-EPR3 asthma guidelines : A practical perspective. / Zeki, Amir; Kenyon, Nicholas; Louie, Samuel.
In: Journal of Respiratory Diseases, Vol. 29, No. 12, 12.2008, p. 481-487.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The NAEPP-EPR3 asthma guidelines
T2 - A practical perspective
AU - Zeki, Amir
AU - Kenyon, Nicholas
AU - Louie, Samuel
PY - 2008/12
Y1 - 2008/12
N2 - The latest asthma guidelines are characterized by an increased focus on asthma control and individualized treatment to reduce the patient's impairment and risk of exacerbations. The main components of care include frequent assessment of control and monitoring, patient education, control of environmental triggers, and evaluation of the effectiveness of medications. Failure to treat comorbid conditions, such as rhinosinusitis, and insufficient use of spirometry or peak-flow monitoring are common pitfalls. Inhaled corticosteroids (ICSs) continue to be the mainstay of therapy. Long-acting ß2-agonists are the preferred add-on treatment for patients with persistent asthma who have not adequately responded to an ICS alone. For patients with poorly controlled asthma, close monitoring at 2- to 6-week intervals is recommended. Once control is achieved, follow-up at 1- to 6-month intervals is appropriate.
AB - The latest asthma guidelines are characterized by an increased focus on asthma control and individualized treatment to reduce the patient's impairment and risk of exacerbations. The main components of care include frequent assessment of control and monitoring, patient education, control of environmental triggers, and evaluation of the effectiveness of medications. Failure to treat comorbid conditions, such as rhinosinusitis, and insufficient use of spirometry or peak-flow monitoring are common pitfalls. Inhaled corticosteroids (ICSs) continue to be the mainstay of therapy. Long-acting ß2-agonists are the preferred add-on treatment for patients with persistent asthma who have not adequately responded to an ICS alone. For patients with poorly controlled asthma, close monitoring at 2- to 6-week intervals is recommended. Once control is achieved, follow-up at 1- to 6-month intervals is appropriate.
KW - Allergy
KW - Asthma
KW - NAEPP guidelines
UR - http://www.scopus.com/inward/record.url?scp=76649106742&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=76649106742&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:76649106742
VL - 29
SP - 481
EP - 487
JO - Journal of Respiratory Diseases - For Pediatricians
JF - Journal of Respiratory Diseases - For Pediatricians
SN - 0194-259X
IS - 12
ER -